Amyris Biotechnologies - Top 20 VC deals of 2008

Amyris Biotechnologies, FierceBiotech top venture capital deal of 2008Company: Amyris Biotechnologies
Based: Emeryville, CA
Amount: $65.11M

Investors: Khosla Ventures, Duff Ackerman & Goodrich, TPG Growth, Kleiner Perkins Caufield & Byers, Undisclosed Venture Firm

Scoop: Amyris is a renewable products company which is developing solutions for transportation energy and climate issues. Under a non-profit initiative, Amyris is applying its technology to provide a second source of artemisinin, an anti-malarial therapy, which will be commercialized by Sanofi. Artemisinin is derived from a rare African tree. Rather than trying to cultivate the tree, Amyris is using synthetic biology to produce the derivative in the lab, which will make the drug more affordable and easier to produce.

Amyris Biotechnologies - Top 20 VC deals of 2008
Read more on

Suggested Articles

Karen DeSalvo's appointment is the latest in a string of hires that deepen the tech giant’s investment in and focus on healthcare.

Spring Bank’s hepatitis B drug, given in tandem with Gilead’s Vemlidy, tamped down on chronic disease in 23% of patients in a phase 2 study.

Verseau will use the money to start testing its macrophage checkpoint modulators in humans.